

CURRICULUM VITAE

Name: Meena B. Bansal
Date of Birth: November 24, 1968
Place of Birth: London, Ontario, Canada

Education:

1990 A.B. Harvard University, Boston, MA
1994 M.D. Cornell University Medical College, New York, NY

Postdoctoral Training:

1994-1995 Intern in Medicine, The New York Hospital-Cornell Medical Center, New York, NY
1995-1997 Resident in Medicine, The New York Hospital-Cornell Medical Center, New York, NY
1997-1998 Postdoctoral Research Fellow, The New York Hospital-Cornell Medical Center, New York, NY
1998-2001 Fellowship, Gastroenterology, Hospital of the University of Pennsylvania, Philadelphia, PA

Research Training:

1990 Undergraduate Honors Thesis (*summa cum laude*), Harvard University
1998 Postdoctoral Research Fellow, Dr. Andrew Dannenberg, Cornell University Medical College, New York, NY
1999-2001 Research Fellow, Dr. Rebecca Taub, University of Pennsylvania, Philadelphia, PA

Licensure:

1998 American Board of Internal Medicine, Certificate No. 176704
2001 New York License, No. 201581
2001 Diplomate in Gastroenterology
2008 Diplomate in Transplant Hepatology

Academic Appointments:

1998-2001 Clinical Fellow in GI, University of Pennsylvania, Philadelphia, PA
2001-2012 Assistant Professor of Medicine, Mount Sinai School of Medicine, New York, NY
2012-present Associate Professor of Medicine, Mount Sinai School of Medicine, New York, NY

Hospital Appointments:

- 2001-2011 Assistant Professor of Medicine, Mount Sinai School of Medicine, New York, NY
- 2002-2009 Transplant Hepatology Fellowship Director, Mount Sinai School of Medicine, New York, NY
- 2012- Associate Professor of Medicine, Mount Sinai School of Medicine, New York, NY
- 2013-2015 Medical Director, Hospital-Based Practices, The Mount Sinai Hospital, New York, NY
- 2015- Deputy Chief Medical Officer, Mount Sinai Health Partners
Chief Medical Officer, Mount Sinai Care LLC
- 2017- Vice President, Population Health Quality and Efficiency

Awards and Honors:

- 1986-1990 Elizabeth Cary Agassiz Award(1986-89)
Harvard College Scholarship(1986-89)
John Harvard Scholarship(1989-90)
- 1992 Gustave Noback Memorial Prize in Anatomy. Cornell Medical College. *Selected by the Chairman of Department of Cell Biology and Anatomy for outstanding performance in the field of Anatomy and Cell Biology.*
- 1994 Janet M. Glasglow Memorial Citation. Cornell Medical College. *Awarded by the American Medical Women's Association, Inc. to women students graduating in the top of their class.*
- 1994 David Drusin Memorial Prize. Cornell Medical College. *Awarded to the student who has attained scholastic achievement in medicine and possesses those intangible human qualities associated with being an exceptional physician.*
- 1994 Alpha Omega Alpha Medical Honor Society
- 1997 David E. Rogers Memorial Prize. The New York Hospital-Cornell University Medical College. *Awarded for most outstanding research during residency training.*
- 1997 C. Richard Bowman Memorial Award. The New York Hospital-Cornell University Medical College. *Awarded for most outstanding clinical performance during residency training.*
- 2001 First Prize Komarov Competition-Basic Science. Philadelphia, PA. *Awarded to GI fellow performing most outstanding basic research in all Philadelphia programs.*

- 2005 American Gastroenterological Association: Miles and Shirley Fiterman Basic Research Award
- 2006 Dr. Harold and Golden Lamport Research Award
- Regal Awards: Research Excellence in GI and Liver

Major Committee Assignments:

Mount Sinai School of Medicine

- 2001- Intern Selection Committee
- 2002-2009 Transplant Hepatology Fellowship Program Director
- 2002- Transplant Hepatology Fellowship Admissions Committee
- 2003- Gastroenterology Fellowship Admissions Committee
- 2003-2007 Department of Medicine Research Day Abstract Selection Committee
- 2006-2008 GCRC Advisory Committee
- 2012-2013 MSSM IRB Committee Member
Tisch Cancer Center Grant Review Committee
- 2013- Faculty Affairs Committee
- 2014- Executive board member of MSSP (ACO)
Steering Committee Medicaid Risk Contract Group
- 2015- Chair, Ambulatory Quality Committee
- 2016- Co-Chair MACRA Strategy Committee
MSH 340B Workgroup
MSHP Clinical Integration and Oversight Committee
MSHP Finance and Audit Committee

American Association for the Study of Liver Diseases

- 2006-2008 Training and Workforce Committee
-Co-Director, Career Development Workshop AASLD 2007
-Director, Career Development Workshop AASLD 2008
- 2008 Postgraduate Course Speaker: HCV, HIV, and Molecular Mechanisms of Fibrogenesis
- 2008-2011 Abstract Review Committee (AASLD and DDW)
- 2009 Moderator for Parallel Session: Hepatic Stellate Cell Biology
Moderator Early Morning Workshop: Fibrosis: Mechanisms
- 2011 Moderator Early Morning Workshop: Stellate Cell Biology
Moderator Parallel Session: Stellate Cell Biology
Asked to serve as Co-Organizer for next International Fibrosis Single Topic Conference (AASLD sponsored)
- 2012 Moderator Parallel Session: Fibrosis
Panelist for Scientific Sessions TV: Hepatic Fibrosis
- 2011- AASLD/ALF Joint Research Awards Committee
- 2012-2015 Elected to Fibrosis SIG Steering Committee (AASLD)
- 2013 Elected by membership to AASLD Nominating Committee

- 2014-2016 Chair, AASLD Women's Health Representative Group
 Co-Organizer of Professional Development Workshop
 Co-Director, Gastroenterology Women's Coalition (AGA, AASLD, ASGE, and NASPHGAN)
 Vice Chair, AASLD Research Awards Committee
 Guest Editor, Clinical Liver Disease
 Liver Fibrosis SIG-Webinar organizer
- 2016- Chair, AASLD Research Awards Committee
 Vice Chair, Fibrosis SIG (To become chair in 2018)
 Co-Director Liver Fibrosis Single Topic Conference
 Advisor to AASLD Foundation Board
- 2017- Liver Capital Hill Day Participant (with 2 patients)

American Gastroenterological Association

- 2017-2018 Councilor to Liver and Biliary Section

AIDS Research Advisory Council

- 2014-2018 Selected as Subject Group Member on behalf of NIH/CDC/HIVMA/IDSA monitor Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-infected Adults and Adolescents.

Harvard University

- 1999- Interviewer for Admissions Committee

Memberships in Professional Societies:

- American Association For The Study of Liver Diseases
 American Gastroenterological Association

Service to Public and Non-Profit Agencies:

- 2001- Journal Reviewer for:
Gastroenterology
Hepatology
Journal of Hepatology
Laboratory Investigation
Digestive Diseases and Sciences
Liver International
PLoS One
- 2011- Editorial Board, *Hepatology*
- 2013- Data Safety Monitoring Board for TREAT consortium

Major Research Interests:

- Cellular and molecular mechanisms of liver injury and fibrosis

- Role of chemokine receptors, CXCR4 and CCR5, in stellate cell biology and fibrogenesis
- HIV infection of non-parenchymal cells of the liver and relevance to chronic inflammation and fibrosis
- Treatment of HCV with new DAA's in HCV monoinfected and HIV/HCV coinfecting patients
- Novel therapies for treatment of NASH

Past and Current Trainees:

Postdoctoral Fellows, Visiting Scientists, and Junior Faculty:

- Brian Radbill, M.D. (2002-2005), Nephrology Division. Awardee: NIH NRSA Grant. Current Status: Associate Professor of Medicine; CMO, Mount Sinai St. Lukes
- Yukiko Inoue, M.D. PhD. (2005-2007). Visiting Scientist. University of Tokyo, Japan
- Isabella Swindenbank (2012). Visiting PhD student. University of Birmingham, UK
- Ankur Panchal M.D. (2014-2016). Postdoctoral Fellow.
- Tatyana Kushner, M.D. (2017-) Junior Faculty. Research Mentor

Residents:

- Raluca Vrabie, M.D. (2004-2006). Medicine Resident. Current Status: Gastroenterology Faculty, Winthrop Hospital
- Ritu Agarwal, M.D. (2006-2008). Medicine Resident. Current Status: Hepatology Faculty. Mount Sinai School of Medicine. New York, NY
- Ana Tuyama, M.D. (2006-2007). Medicine Resident. Current Status: Private Practice.
- Yedidya Saiman(2012-2015). Medical Resident. GI Fellowship UPenn

Fellows:

- Ritu Agarwal, M.D. (2008-2009). Clinical GI Fellow. Currently MSSM Faculty
- Ana Tuyama, M.D. (2007-2009). Private Practice
- Charlie Wang, M.D./PhD (2008-2012). Fast track MSSM Medicine Resident. Currently Faculty at NYU
- James Crismale (2015-) GI Fellow.

Postgraduate Students:

- Ritu Gupta (2002-2004; 2006-2008). Assistant Researcher. Current Status: Internal Medicine Resident, Yale University
- Derya Ozkok (7/2007-6/2008). Assistant Researcher. Current Status: Medical Resident
- Ankur Panchal (2014-2016). MD. Medicine Resident

Graduate Students:

- Yedidya Saiman (2007-2013). MD/PhD student. GI Fellow UPenn

Undergraduate Students:

- Riti Bhalla (2013-2015). Medical School

High-school students:

- Akansha Agarwal (2002), Summer Research Student. Intel Competition. Current Status: Physician Assistant
- Anita Garg (2006), Summer Research Student. Intel Competition. Current Status: Rehab Resident (Kessler)

Selected Invited Lectures:

Bansal MB, Subbaramaiah K, Dannenberg AJ. *Transcription of Cyclooxygenase-2 is Enhanced in Transformed Mammary Epithelial Cells*. The New York Hospital-Cornell Medical Center. Medical Grand Rounds: June 5, 1997.

Bansal MB, Kovalovich K, Li W, Taub RA. *IL-6 protects against liver injury and fibrosis via its effects on matrix degradation*. Annual Meeting of American Association For the Study of Liver Diseases. Dallas, TX. November 9, 2001.

Bansal MB. *Bioartificial Livers: Progress and Prospects*. Mount Sinai Medical Grand Rounds. November 2001.

Bansal MB. *Interleukin-6 attenuates acute toxin-induced liver injury and apoptosis in mice reducing matrix metalloproteinase-2*. AGA Academic Skills Workshop for Junior Faculty. Sarasota, FL, September 27, 2002.

Bansal MB. *MMP-2 in liver fibrosis: Friend or Foe?* Department of Medicine Research Conference. June 2, 2005.

Bansal MB. *Fulminant Hepatic Failure: Important to Recognize and Refer*. First Annual Hepatology Update. Mount Sinai School of Medicine. September 23, 2005.

Bansal MB. *Role of CXCR4 in stellate cell biology and fibrogenesis*. Center for the Study of Hepatitis C. Weill Cornell University Medical Center. December 8, 2005.

Bansal MB. *Hepatic Stellate Cells Express Functional CXCR4: Implications for HIV/HCV-Mediated Liver Fibrosis*. Center for the Study of Hepatitis C. Rockefeller University. October 17, 2006.

Bansal MB. *Hepatic Stellate Cells Express Functional CXCR4: Implications for HIV/HCV-Mediated Liver Fibrosis*. Mount Sinai Infectious Disease Research Conference. January 10, 2007.

Bansal MB. *Hepatic Stellate Cells Express Functional CXCR4: Implications for HIV/HCV-Mediated Liver Fibrosis*. Johns Hopkins School of Medicine. Hepatitis Divisional Conference. March 27, 2007.

Bansal MB. Hepatic Stellate Cells Express Functional CXCR4: Implications for HIV/HCV-Mediated Liver Fibrosis. Mount Sinai School of Medicine, Department of Medicine Grand Rounds. July 17, 2007.

Bansal MB. Mechanisms of Liver Fibrosis. Mount Sinai Pediatric Liver Symposium. April 12, 2008.

Bansal MB. HCV, HIV, and Molecular Mechanisms of Fibrogenesis, AASLD Postgraduate Course. San Francisco, CA. Nov 1, 2008.

Bansal MB. HCV, HIV, and Molecular Mechanisms of Fibrogenesis. 5th International Coinfection Workshop. Lisbon, Portugal. June 4, 2009.

Schuppan D and **Bansal MB.** Fibrosis: Mechanisms. Early Morning Basic Workshop. AASLD Annual Meeting. Boston, MA. Nov. 3, 2009.

Bansal MB. New Advances and Technologies in Diagnosis and Treatment. Science in the City. Best of AASLD and HCV update. New York, NY. Nov. 14, 2009.

Bansal MB. Stellate Cell Activation in the Setting of HIV. HIV and Liver Disease 2010 Conference. Jackson Hole, WY. September 25, 2010.

Bansal MB. Hepatic Stellate Cell-HIV Interactions: Implications for Rapid Liver Fibrosis Progression in HIV/HCV Coinfected Patients. MSSM DOM Research Conference. April, 7, 2011.

Bansal MB. Hepatic Stellate Cell-HIV Interactions: Implications for Rapid Liver Fibrosis Progression in HIV/HCV Coinfected Patients. MSSM Department of Medicine Grand Rounds. June 14, 2011.

Bansal MB. Hepatic Stellate Cell-HIV Interactions: Implications for Rapid Liver Fibrosis Progression in HIV/HCV Coinfected Patients. Bronx-Lebanon Division of Gastroenterology Grand Rounds. March 8, 2012.

Bansal MB. Stromal – Tumor crosstalk by SDF1- α /CXCL12 in HCC Development and Growth. Tisch Cancer Center Retreat. New York Academy of Sciences. New York, NY. April 17, 2012.

Bansal MB. HIV/HCV/DAA. Science in the City. Mount Sinai School of Medicine. New York, NY. December 1, 2012

Bansal MB. HIV and hepatic inflammation and fibrosis. Divisional Grand Rounds. Albert Einstein School of Medicine. Bronx, NY. March 13, 2013.

Bansal MB. Care of the Patient with End-Stage Liver Disease-The Role of the Internist. American College of Physicians. San Francisco, CA. April 11, 2013.

Bansal MB. HIV and hepatic inflammation and fibrosis. Divisional Grand Rounds. Stony Brook School of Medicine. Stony Brook, NY. April 17, 2013.

Bansal MB. Acute Liver Failure. Mount Sinai Gastroenterology and Hepatology Board Review Course. New York, NY. August 15, 2013

Bansal MB. Acute Liver Failure and Transplantation. Medical Grand Rounds. UMDNJ-Robert Wood Johnson Medical School. New Brunswick, NJ. September 25, 2013.

Bansal MB. Acute Liver Failure and Artificial Liver Supports. Medical Grand Rounds. Phelps Memorial Hospital. Sleepy Hollow, NY. October 25, 2013.

Bansal MB. DDW Translational Research Symposium: Hepatic Fibrosis. Chicago, IL. May 4, 2015.

Bansal MB. Role of Stellate Cell Activation and Fibrogenesis in HIV. HIV and Liver Disease Conference 2014. Jackson Hole, Wyoming. Sept 19, 2014.

Bansal MB. NASH Update. Science in the City. Icahn School of Medicine at Mount Sinai. New York, NY. November 15, 2014.

Bansal MB. Acute Liver Failure. Mount Sinai Gastroenterology and Hepatology Board Review Course. New York, NY. August 13, 2015.

Bansal MB. Advances in Understanding Hepatic Fibrosis and its Treatment. Science in the City. New York, NY. November 21, 2015.

Bansal MB and Jubelt L. Building Blocks for Population Health: The Health System Perspective. HealthCare Web Summit. October 20, 2016.

Bansal MB. Understanding MACRA: An Overview Of Medicare's New Quality Payment Program. MSQ Physician Quarterly Conference. October 27, 2016.

Bansal MB. CIN Update. Mount Sinai Health Partners Town Hall. March 7, 2017

Bansal MB. Supporting Quality Performance, Appropriate Risk Adjustment and Efficiency. Mount Sinai Primary Care Town Hall. June 8, 2017.

Bansal MB. Mount Sinai NASH Symposium. New York, NY. November 10, 2017

Bansal MB. NASH-Therapeutics in 2017 and Beyond. Science in the City. New York, NY. November 11, 2017

Bansal MB. Controlling Costs: Approach by an Urban Academic Medical System. CAPG-CMS Webinar Series. December 1, 2017.

Bansal MB. Intermediate Surrogate Markers for Therapeutic Response in Patients with Cirrhosis. AASLD Industry Colloquium: Novel Targets and Therapies in Liver Disease. Rockville, MD. January 19, 2017.

Current Research Support:

M. Bansal, PI
1R01DK108364

9/23/15-08/31/2020 total project period

HIV and hepatic inflammation and fibrosis

Active Clinical Trials:

Tobira Therapeutics, Inc. (**PI, Bansal**)
12/2014-

CENTAUR: Efficacy and Safety Study of Cenicriviroc for the Treatment of NASH in Adult Subjects with Fibrosis

Intercept Pharmaceuticals (**PI, Bansal**)
06/2016-

747-303- A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis - The REGENERATE Study

Madrigal Pharmaceuticals, Inc. (**PI, Bansal**)
10/2016-

A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis

Past Clinical Trials:

Pfizer Inc., U.S. Pharmaceuticals Group (**PI, Bansal**)

A Multicenter, Randomized, Blinded, Placebo-Controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In HIV-1-Infected Subjects Co-Infected With Hepatitis C and/or Hepatitis B Virus

Gilead Sciences (**PI, Bansal**)

A Phase 3, Open-label Study to Investigate the Efficacy and Safety of GS-7977 plus Ribavirin for 12 Weeks in Chronic Genotype 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Subjects [GS-US-334-0123]

Vertex Pharmaceuticals Incorporated (**PI, Bansal**)

EXTEND: A 3-Year, Virology Follow up Study in Subjects Previously Treated with Telaprevir in Select Clinical Studies [VX08-950-112]

Gilead Sciences (**PI, Bansal**)

A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks in Subjects with Chronic

Genotype 1 or 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Co-Infection

Kinemed (Co-I, Bansal)

Biomarkers of Liver Fibrosis

The goal of the project is to determine whether the regression of scar in the liver can be predicted based on the half-life of serum proteins and what is the identity of the proteins that are the best indicators of liver scar formation and regression

Gilead Sciences (PI, Bansal)

A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 8 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks in Subjects with Chronic Genotype 3 HCV Infection and Cirrhosis

Gilead Sciences (PI, Bansal)

A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 12 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks in Direct-Acting Antiviral-Experienced Subjects with Chronic HCV Infection who Have Not Received an NS5A Inhibitor

Past Support:

1. M. B. Bansal, PI, "IL-6 Regulation of Matrix Degradation in Liver Fibrosis." NIH DK60474-04. Award Dates: February 1, 2002 –June 30, 2008. Annual direct costs, \$113,825.

2. M.B. Bansal, PI, "Role of Matrix Metalloproteinase-2 in Liver Fibrosis" NIH DK DK071745. Award Dates: August 1, 2006- July 31, 2008. Annual direct costs, \$50,000.

3. M.B. Bansal, PI, " Matrix Metalloproteinase-2 Induction in Liver Injury: An adaptive response to fibrosis?" American Gastroenterological Association/Miles and Shirley Fiterman Foundation Basic Research Awards. Award Dates: July 1, 2005- June 30, 2006. Direct costs, \$35,000.

4. M. B. Bansal, PI. "Stellate Cell-HIV interactions and Hepatic Fibrosis" NIH/NIDDK R56 DK092128. Award Dates: 9/23/11-8/31/13. Annual direct costs: \$218,000.

5. M. Bansal, Co-PI

1U01DK100928-01 (Odin/Ahmad)

NIH/NIDDK

Continuation of the Clinical Centers for the Drug Induced Liver Injury Network [DILIN]
06/01/13-05/31/14

Publications:

Peer reviewed articles:

Lipkin M, **Bhandari M**, Hakissian M, Croll W, Wong G. Surrogate Endpoint Biomarker Assays in Phase II Chemoprevention Clinical Trials. *J Cell Biochem Suppl.* 1994;19:47-54.

Boyle B, **Bansal MB**, Merrick S, Jacobs J. Pulmonary Symptoms in AIDS Patients: The Need For Early Bronchoscopy. *The AIDS Reader.* 1997. 7(4):112-115.

Subbaramaiah K, Telang N, **Bansal MB**, Weksler BB, Dannenberg AJ. Cyclooxygenase-2 Gene Expression is Up-regulated in Transformed Mammary Epithelial Cells. *Ann NY Acad Science.* 1997. 833:179- 185.

Blecker D, **Bansal MB**, Zimmerman RL, Kochman RL, Fogt F, Stein R. Dieulafoy's lesion of the small bowel causing massive gastrointestinal bleeding: case reports and literature review. *American Journal of Gastroenterology.* 2001; 96(3):902-905.

Bansal MB, Scott L, Friedman. The enlarging role of matrix metalloproteinases in liver injury - beyond scar degradation. *Journal of Hepatology* 2002 Aug;37(2):293-4.

Safadi R, Ohta M, Alvarez CE, Fiel MI, **Bansal MB**, Mehal WZ, Friedman SL. Immune Stimulation of Hepatic Fibrogenesis by CD8 Lymphocytes and its Attenuation by Transgenic Interleukin 10 from Hepatocytes. *Gastroenterology* 2004; 127: 870-82.

Bansal MB, Kovalovich K, Li W, Gupta R, Agarwal A, Alvarez CE, Safadi R, Radbill B, Friedman SL, Taub RA. Interleukin-6 Protects Hepatocytes from CCl₄- Mediated Necrosis and Apoptosis in Mice by Reducing MMP-2 Expression. *Journal of Hepatology.* 2005; 42:548-56

Kodali R, Hajjou M, Berman AB, **Bansal MB**, Zhang S, Pan JJ, Schechter AD. Chemokines Induce Matrix Metalloproteinase-2 Through Activation of Epidermal Growth Factor Receptor in Arterial Smooth Muscle Cells. *Cardiovascular Research.* 2006; 69:706-715.

Feng Hong, Ana Tuyama, Ritu Agarwal, Ritu Gupta, Xin Cheng, Anita Garg, Yukiko Inoue, M. Isabel Fiel, Myron Schwartz, Martina Schwarzkopf, Alison D. Schechter, and **Meena B. Bansal**. Hepatic Stellate Cells Express Functional CXCR4: Role in Stromal Cell Derived Factor -1 α mediated Stellate Cell Activation. *Hepatology.* 2009; 49: 2055-2067.

Ana C. Tuyama*, Feng Hong*, Yedidya Saiman, Chuansheng Wang, Arevik Mosoian, Ping Chen, Benjamin K. Chen, Mary Klotman, and **Meena B. Bansal**. HIV-1 Infects Human Hepatic Stellate Cells and Promotes Collagen I and MCP-1 Expression: Implications for hepatic fibrosis in HIV/HCV co-infection. *Hepatology.* 2010; 52: 612-621.

Brian Radbill, Ritu Gupta, Maria Celeste M. Ramirez, Analisa DiFeo, John Martignetti, Carlos Alvarez, Scott L. Friedman, Goutham Narla, Raluca Vrabie, Yedidya Saiman, Robert Bowles, and **Meena B. Bansal**. Loss of Matrix Metalloproteinase-2 Amplifies Murine Toxin Induced Liver Fibrosis by Upregulating Collagen I Expression. *Digestive Diseases and Sciences*. 2011; 56: 406-416 (Epub 2010 June 19). PMID: 20563750. PMCID: PMC2964408.

Feng Hong, Yedidya Saiman, Chuanping Si, and **Meena B. Bansal**. X4 Human Immunodeficiency Virus Type 1 gp120 promotes Human Hepatic Stellate Cell Activation and Collagen I Expression through Interactions with CXCR4. **PLoS One**. 2012;7(3):e33659. Epub 2012 Mar 27. PMID: 22479424. PMCID: PMC3313947

Michel Fausther, Nina Sheung, Yedidia Saiman, **Meena B. Bansal**, Jonathan A. Dranoff. Activated Hepatic Stellate Cells Upregulate Transcription of Ecto-5'-Nucleotidase/CD73 via Specific SP1 and SMAD Promoter Elements. **AJP Gastrointestinal and Liver Physiology**. 2012 Oct; 303(8): G904-14. PMID: 22899823. PMCID: PMC3469697

Saiman Y, Agarwal R, Hickman DA, Fausther M, El-Shamy A, Dranoff JA, Friedman SL, Bansal MB. CXCL12 induces hepatic stellate cell contraction through a calcium independent pathway. **Am J Physiol Gastrointest Liver Physiol**. 2013 Jun 27. [Epub ahead of print] PMID: 23812037

Diabetes mellitus and advanced liver fibrosis are risk factors for severe anaemia during telaprevir-based triple therapy. Crismale JF, Martel-Laferrière V, Bichoupan K, Schonfeld E, Pappas A, Wyatt C, Odin JA, Liu LU, Schiano TD, Perumalswami PV, **Bansal M**, Dieterich DT, Branch AD. *Liver Int*. 2013 Oct 1. doi: 10.1111/liv.12342. [Epub ahead of print] PMID: 24118693

Effect of fibrosis on adverse events in patients with hepatitis C treated with telaprevir. Bichoupan K, Schwartz JM, Martel-Laferriere V, Giannattasio ER, Marfo K, Odin JA, Liu LU, Schiano TD, Perumalswami P, **Bansal M**, Gaglio PJ, Kalia H, Dieterich DT, Branch AD, Reinus JF. *Aliment Pharmacol Ther*. 2014 Jan;39(2):209-16. doi: 10.1111/apt.12560. Epub 2013 Nov 24. PMID: 24266536

Inhibition of the CXCL12/CXCR4 chemokine axis with AMD3100, a CXCR4 small molecule inhibitor, worsens murine hepatic injury. Saiman Y, Jiao J, Fiel MI, Friedman SL, Aloman C, **Bansal MB**. *Hepato Res*. 2014 Aug 28. doi: 10.1111/hepr.12411. [Epub ahead of print] PMID: 25163538

Telaprevir activity in treatment-naive patients infected with hepatitis C virus genotype 4. Sefcik RK, Bichoupan K, Martel-Laferrière V, Odin JA, Liu LU, Perumalswami P, **Bansal M**, Dieterich DT, Ahmad J, Schiano TD, Branch AD. *J Infect Dis*. 2014 Dec 1;210(11):1855-6. doi: 10.1093/infdis/jiu360. Epub 2014 Jun 26.

Hepatic safety in subjects with HIV-1 and hepatitis C and/or B virus: a randomized, double-blind study of maraviroc versus placebo in combination with antiretroviral agents.

Rockstroh JK, Soriano V, Plonski F, Bansal M, Fätkenheuer G, Small CB, Asmuth DM, Pialoux G, Mukwaya G, Jagannatha S, Heera J, Pineda JA. HIV Clin Trials. 2015 Mar-Apr;16(2):72-80. PMID: 25923596

Biliary Epithelial Cells Are Not the Predominant Source of Hepatic CXCL12. Saiman Y, Sugiyama T, Simchoni N, Spirli C, **Bansal MB**. Am J Pathol. 2015 Apr 28. pii: S0002-9440(15)00195-9. doi: 10.1016/j.ajpath.2015.03.006. [Epub ahead of print] PMID: 25934614

Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. Naggie s et al.; ION-4 Investigators. N Engl J Med. 2015 Aug 20;373(8):705-13. doi: 10.1056/NEJMoa1501315. Epub 2015 Jul 21. PMID: 26196665

Hepatic decompensation/serious adverse events in post-liver transplantation recipients on sofosbuvir for recurrent hepatitis C virus. Patel N, Bichoupan K, Ku L, Yalamanchili R, Harty A, Gardenier D, Ng M, Motamed D, Khaitova V, Bach N, Chang C, Grewal P, **Bansal M**, Agarwal R, Liu L, Im G, Leong J, Kim-Schluger L, Odin J, Ahmad J, Friedman S, Dieterich D, Schiano T, Perumalswami P, Branch A. World J Gastroenterol. 2016 Mar 7;22(9):2844-54. doi: 10.3748/wjg.v22.i9.2844. PMID: 26973423

Interleukin-15 receptor α on hepatic stellate cells regulates hepatic fibrogenesis in mice. Jiao J, Ooka K, Fey H, Fiel MI, Rahmman AH, Kojima K, Hoshida Y, Chen X, de Paula T, Vetter D, Sastre D, Lee KH, Lee YA, **Bansal M**, Friedman SL, Merad M, Aloman C. J Hepatol. 2016 Aug;65(2):344-53. doi: 10.1016/j.jhep.2016.04.020. PMID:27154062

Toxin-Induced Autoimmune Hepatitis Caused by Raw Cashew Nuts. Crismale JF, Stueck A, **Bansal M**. ACG Case Rep J. 2016 Sep 28;3(4):e133. PMID:27807585

Hepatic stellate cells: fibrogenic, regenerative or both? Heterogeneity and context are key. **Bansal MB**. Hepatol Int. 2016 Nov;10(6):902-908. Review. PMID: 27578210

Frontline Science: HIV infection of Kupffer cells results in an amplified proinflammatory response to LPS. Mosoian A, Zhang L, Hong F, Cunyat F, Rahman A, Bhalla R, Panchal A, Saiman Y, Fiel MI, Florman S, Roayaie S, Schwartz M, Branch A, Stevenson M, **Bansal MB**. J Leukoc Biol. 2016 Dec 16. pii: jlb.3HI0516-242R. [Epub ahead of print]

Hepatitis C virus double-stranded RNA is the predominant form in human liver and in interferon-treated cells. Klepper A, Eng FJ, Doyle EH, El-Shamy A, Rahman AH, Fiel MI, Avino GC, Lee M, Ye F, Roayaie S, **Bansal MB**, MacDonald MR, Schiano TD, Branch AD. Hepatology. 2016 Sep 19. doi: 10.1002/hep.28846. [Epub ahead of print] PMID:27642141

Hepatic safety of maraviroc in patients with HIV-1 and hepatitis C and/or B virus: 144-week results from a randomized, placebo-controlled trial. Rockstroh JK, Plonski F, **Bansal M**, Fätkenheuer G, Small CB, Asmuth DM, Pialoux G, Zhang-Roper R, Wang R, Pineda JA, Heera J. *Antivir Ther.* 2016 Dec 7. doi: 10.3851/IMP3116. [Epub ahead of print] PMID: 27924779

Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results. Bichoupan K, Tandon N, Crismale JF, Hartman J, Del Bello D, Patel N, Chekuri S, Harty A, Ng M, Sigel KM, **Bansal MB**, Grewal P, Chang CY, Leong J, Im GY, Liu LU, Odin JA, Bach N, Friedman SL, Schiano TD, Perumalswami PV, Dieterich DT, Branch AD. *World J Virol.* 2017 Nov 12;6(4):59-72. PMID: 29147645

Estrogen decreases tight junction protein ZO-1 expression in human primary gut tissues. Zhou Z, Zhang L, Ding M, Luo Z, Yuan S, **Bansal MB**, Gilkeson G, Lang R, Jiang W. *Clin Immunol.* 2017 Oct;183:174-180. doi: 10.1016/j.clim.2017.08.019. Epub 2017 Sep 1. PMID: 28867253

Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. Bourlière M, Gordon SC, Flamm SL, Cooper CL, Ramji A, Tong M, Ravendhran N, Vierling JM, Tran TT, Pianko S, **Bansal MB**, de Ledinghen V, Hyland RH, Stamm LM, Dvory-Sobol H, Svarovskaia E, Zhang J, Huang KC, Subramanian GM, Brainard DM, McHutchison JG, Verna EC, Buggisch P, Landis CS, Younes ZH, Curry MP, Strasser SI, Schiff ER, Reddy KR, Manns MP, Kowdley KV, Zeuzem S; POLARIS-1 and POLARIS-4 Investigators. *N Engl J Med.* 2017 Jun 1;376 (22):2134-2146. doi: 10.1056/NEJMoa1613512. PMID: 28564569.

Textbook Chapters, Editorials and Invited Reviews

Bansal MB, Friedman SL. Fibrogenesis. In: *Encyclopedia of Gastroenterology*, San Diego: Elsevier, Academic Press, 2004:34-38.

Bansal MB, Friedman SL. Future Treatments: Anti-fibrotic agents, nitric oxide donors, and gene therapy in the treatment of portal hypertension. In *Portal Hypertension: Pathobiology, Evaluation, and Treatment*, Totowa: Humana Press Inc., 2005:485-503.

Friedman SL and **Bansal MB**. Reversal of Hepatic Fibrosis-Fact or Fantasy? *Hepatology* 2006; 43:S82-88.

Bansal MB. Third-tier fellowship training in hepatology: advantages and program selection. *Gastrointestinal Endoscopy.* 2006; 63(4): 674-675.

Bansal MB and Friedman SL. Hepatic Fibrogenesis. In *Sherlock's Diseases of the Liver and Biliary System*, 12th edition: 94-101. 2011.

Bansal MB and Blackard J. Effect of HIV on Liver Cell Populations. In HIV and Liver Diseases, Springer: 81-90. 2011.

Bansal MB. Acute Liver Failure. In Mount Sinai Expert Guides: Hepatology, Wiley Blackwell: 280-293. 2014

Bansal MB. Guest Editor. The Future in Liver Medicine. Clinical Liver Disease. 2015

Bansal MB. Invited Review. Hepatic Stellate Cells: Fibrogenic, Regenerative or Both?: Heterogeneity and Context Are Key. Hepatology Research. Hepatol Int. 2016 Nov;10(6):902-908. Review. PMID: 27578210